Benitec Biopharma (BNTC) Operating Margin (2019 - 2023)

Benitec Biopharma has reported Operating Margin over the past 5 years, most recently at 65000.0% for Q2 2023.

  • Quarterly results put Operating Margin at 65000.0% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 307028.57% (down 27869181.0% YoY), and the annual figure for FY2023 was 25441.33%, down 98380.0%.
  • Operating Margin reached 65000.0% in Q2 2023 per BNTC's latest filing, down from 8038.89% in the prior quarter.
  • Across five years, Operating Margin topped out at 8248.57% in Q2 2020 and bottomed at 379300.0% in Q1 2021.
  • Median Operating Margin over the past 5 years was 8038.89% (2023), compared with a mean of 80620.4%.
  • The largest annual shift saw Operating Margin tumbled -37176071bps in 2021 before it skyrocketed 37209167bps in 2022.
  • Over 5 years, Operating Margin stood at 2741.56% in 2019, then plummeted by -11787bps to 325900.0% in 2020, then soared by 94bps to 19340.0% in 2021, then crashed by -107bps to 40071.43% in 2022, then crashed by -62bps to 65000.0% in 2023.
  • Business Quant data shows Operating Margin for BNTC at 65000.0% in Q2 2023, 8038.89% in Q1 2023, and 40071.43% in Q4 2022.